2018年4月1日
Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection
Gastrointestinal Endoscopy
- 巻
- 87
- 号
- 4
- 開始ページ
- 1114
- 終了ページ
- 1120
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/j.gie.2017.09.040
- 出版者・発行元
- Mosby Inc.
Background and Aims: Rebamipide is administered perorally to protect the gastric mucosa. We assessed the efficacy and safety of a novel rebamipide solution as a submucosal injection material for endoscopic submucosal dissection (ESD) using an in vivo porcine model. Methods: An endoscopist blinded to the test agents performed ESDs of hypothetical 30 mm lesions using a 2% rebamipide solution at 2 sites (rebamipide group) and a saline solution at 2 other sites (control group) in the stomachs of 8 pigs. The technical outcomes were compared between the 2 groups. The gastric ulcer stages were evaluated by endoscopy once weekly for 4 weeks after the ESD to determine the healing score (1-6). The pigs were killed at 1 week (n = 2), 2 weeks (n = 2), and 4 weeks (n = 4) after the ESD for pathologic evaluation of ESD-induced ulcers and scarring. Results: There were no significant differences in any of the technical outcomes between the 2 groups, and no adverse events related to the ESD in any of the animals. The healing score was significantly higher in the rebamipide group than in the control group at 2 weeks (P =.027), 3 weeks (P =.034), and 4 weeks (P =.012). In the histopathologic assessment, fibrosis was significantly less extensive in the rebamipide group than in the control group at 2 weeks (P =.02) and 4 weeks (P =.04). Conclusions: The rebamipide solution appeared to promote both the speed and quality of healing of ESD-induced ulcers by suppressing fibrosis.
- ID情報
-
- DOI : 10.1016/j.gie.2017.09.040
- ISSN : 1097-6779
- ISSN : 0016-5107
- SCOPUS ID : 85036615765